Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Micromet in $990M Collaboration Deal with Amgen

By Pharmaceutical Processing | July 12, 2011

 

NEW YORK
(AP) — Micromet Inc. has licensed three experimental cancer antibodies to Amgen
Inc. in a deal that could be worth $990 million.

Amgen agreed to pay Micromet 10 million euros ($14.3
million) upfront and it will reimburse Micromet for research and development.
The drugs will be studied as treatments for solid tumors. Micromet could get as
much as 342 million euros ($487.3 million) in payments if the drugs reach
development milestones, are approved, and reach sales targets. It will also
receive royalty payments on any sales. Including a cash payment at the start of
a second development program and other payments, Micromet could receive 695
million euros ($990.4 million).

Micromet, of Rockville,
Md., develops drugs that are
designed to train the body’s T cells to target tumor cells. Immune therapies
for cancer have become a major area for research because they have the
potential to treat cancer while sparing healthy cells. Traditional chemotherapy
drugs attack tumor cells and healthy cells at the same time.

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE